In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Digital Health Artificial Intelligence Innovation

Expert Panel Discusses Trends In Digital Health Investment

  • Analysis

Executive Summary

An expert panel at the AdvaMed MedTech Conference in San Francisco discussed trends in digital health investment including market opportunities and regulatory and reimbursement challenges.

You may also be interested in...



Kids, Time To Play Your Medicine: Akili Prepares Launch Of EndeavorRx Video Game For ADHD

After being first to receive FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while targeting other indications.

Kids, Time To Play Your Medicine: Akili Prepares Launch Of EndeavorRx Video Game For ADHD

After being first to receive FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while targeting other indications.

GOP, AdvaMed Endorse US-Mexico-Canada Agreement That Will Impact Billions In Medtech Trade

Republican leaders in the US Senate and House, along with the device industry, are pushing for swift approval by Congress of the US-Mexico-Canada trade agreement (USMCA), which benefits industry through more than $12bn in trade with Mexico each year.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight

Topics

Tags:
Digital Health Artificial Intelligence Innovation
Latest Headlines

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

South Korea Sees Pharma Leadership Transition

FDA-EMA Advice Pilot For Complex Generics: What Does Industry Have To Say?

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

See All
UsernamePublicRestriction

Register

MT125193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By